[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580062":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":23,"locations":29,"responsibleParty":96,"collaborators":11,"id":98,"slug":11,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":11,"eligibilityCriteria":103,"healthyVolunteers":99,"sex":104,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":11,"studyType":110,"phases":111,"briefSummary":113,"conditions":114,"keywords":11,"overallStatus":32,"whyStopped":11,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"Vertex Pharmaceuticals Incorporated","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"VX-880","EXPERIMENTAL",null,[13],"Biological: Biological\u002FVaccine",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Biological\u002FVaccine","Infused into the hepatic portal vein.",[9],[21,22],"Zimislecel","Formerly known as STx-02",[24],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Medical Information","CONTACT","617-341-6777","medicalinfo@vrtx.com",[30,44,53,63,73,81,91],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":11},"Perelman Center for Advanced Medicine - Endocrinology","RECRUITING","Philadelphia","Pennsylvania","19104","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-75.16362,39.95238,{"lat":42,"lon":41},{"facility":45,"status":32,"city":46,"state":34,"zip":47,"country":36,"countryCode":37,"cosmosGeoPoint":48,"geoPoint":52,"contacts":11},"Montefiore Clinical and Translational Research Center - Endocrinology","Pittsburgh","15213",{"type":39,"coordinates":49},[50,51],-79.99589,40.44062,{"lat":51,"lon":50},{"facility":54,"status":32,"city":55,"state":56,"zip":57,"country":36,"countryCode":37,"cosmosGeoPoint":58,"geoPoint":62,"contacts":11},"UW University Hospital - Endocrinology","Madison","Wisconsin","53792",{"type":39,"coordinates":59},[60,61],-89.40123,43.07305,{"lat":61,"lon":60},{"facility":64,"status":32,"city":65,"state":11,"zip":11,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":72,"contacts":11},"Toronto General Hospital - Endocrinology","Toronto","Canada","CA",{"type":39,"coordinates":69},[70,71],-79.39864,43.70643,{"lat":71,"lon":70},{"facility":74,"status":32,"city":75,"state":11,"zip":11,"country":66,"countryCode":67,"cosmosGeoPoint":76,"geoPoint":80,"contacts":11},"Vancouver General Hospital - Gordon and Leslie Diamond Health Care Centre","Vancouver",{"type":39,"coordinates":77},[78,79],-123.11934,49.24966,{"lat":79,"lon":78},{"facility":82,"status":32,"city":83,"state":11,"zip":11,"country":84,"countryCode":85,"cosmosGeoPoint":86,"geoPoint":90,"contacts":11},"King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology","Riyadh","Saudi Arabia","SA",{"type":39,"coordinates":87},[88,89],46.72185,24.68773,{"lat":89,"lon":88},{"facility":92,"status":32,"city":83,"state":11,"zip":11,"country":84,"countryCode":85,"cosmosGeoPoint":93,"geoPoint":95,"contacts":11},"King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology",{"type":39,"coordinates":94},[88,89],{"lat":89,"lon":88},{"type":97,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100580062",false,"NCT06832410","An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant","A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 Diabetes With a Kidney Transplant","Key Inclusion Criteria:\n\n* Clinical history of T1D with greater than or equal to (≥)5 years of insulin dependence\n* Taking a stable immunosuppression regimen of tacrolimus and mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks\n* Consistent use of continuous glucose monitor (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study\n\nKey Exclusion Criteria:\n\n* Prior islet cell transplant, organ transplant (other than kidney transplant), or cell therapy, except prior pancreatic graft that failed within the first 4 weeks\n* Participants had \\>1 kidney transplant procedure\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years","65 Years",{"count":108,"type":109},10,"ESTIMATED","INTERVENTIONAL",[112],"PHASE3","This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.",[115,116],"Type 1 Diabetes","Kidney Transplant","2026-03-18",{"date":119,"type":120},"2026-03-23","ACTUAL",{"date":122,"type":120},"2025-03-31",{"date":124,"type":109},"2027-09-17",{"name":5,"class":6},7]